Cotreatment with Gemand VX-970 confers early disease control and increased overall survival in an orthotopic mouse model of AML. (A) Twenty-four female Rag2^−/−gc^−/− mice were injected intrafemorally (i.f.) with 5 × 10⁵ MV4-11 luc⁺GFP⁺ cells, and treatment with 60 mg/kg VX-970, 100 mg/kg Gem, or both (or vehicle controls) was administered 7 to 21 days after injection, as detailed in the main article text. Bioluminescent imaging was performed at regular intervals to monitor disease burden. Shown are representative mice from each treatment arm at 7, 14, 21, and 28 days after injection. (B) Total flux (used to quantify disease burden) was measured from bioluminescent images during the treatment period. Data represent the mean ± SD for 6 mice in each treatment arm on indicated days after administration of the first dose. Some of the lower error bars (SD) have been omitted because they cannot be plotted on a log scale. (C) Overall event-free survival in each treatment arm was compared by Kaplan-Meier survival analysis. At termination of study on day 165, 4 mice in the VX-970 and Gem cotreatment arm remained alive and disease-free. See supplemental Figure 6. p/s/cm²/sr, photons per second per centimeter squared per steradian.